- Home
- »
- Healthcare IT
- »
-
Artificial Intelligence in Precision Medicine Market Report, 2033GVR Report cover
![Artificial Intelligence In Precision Medicine Market (2026 - 2033)Report]()
Artificial Intelligence In Precision Medicine Market (2026 - 2033)
Size, Share & Trends Analysis Report By Technology (Querying Method, Context aware processing), By Component (Hardware), By Therapeutic Application (Oncology), By Region, And Segment Forecasts
Market Size, 2025
$2.4BMarket Estimate, 2026
$3.4BMarket Forecast, 2033
$32.5BCAGR, 2026–2033
38.3%Artificial Intelligence In Precision Medicine Market Summary
The global artificial intelligence (AI) in precision medicine market size was valued at USD 2.4 billion in 2025 and is projected to grow from USD 3.4 billion in 2026 to USD 32.5 billion by 2033, at a CAGR of 38.3% from 2026 to 2033. North America dominated the AI in precision medicine market with the largest revenue share of 53.3% in 2025. The market growth is primarily driven by increasing investments in R&D and rising demand for personalized medications.
Key Market Trends & Insights
- By technology: Deep learning segment held the largest market share of 33.5% in 2025.
- By component: Software segment held the largest market share of 42.0% in 2025.
- By therapeutic application: Oncology segment held the largest market share of 30.0% in 2025.
Regional Highlights
- Largest regional market: North America (53.3% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025
Market Size & Forecast
- Market size in 2025: USD 2.4 Billion
- Estimated market size in 2026: USD 3.4 Billion
- Projected market size by 2033: USD 32.5 Billion
- CAGR (2026-2033): 38.3%
Collaborations among key companies also play a significant role in driving industry growth. For instance, in August 2022, Enlitic collaborated with GE Healthcare to assist PACS users in enhancing workflow efficiencies through data standardization using Enlitic Curie. The rise in cancer cases across the globe has had a positive impact on the artificial intelligence in precision medicine industry. According to Globocan 2022, globally, around 10 million deaths were caused due to cancer in 2022.
Rising adoption of a sedentary lifestyle and increased alcohol & tobacco consumption are some of the major factors responsible for the rising prevalence of cancer. Moreover, the growing R&D investment drives market growth. The African Access Initiative, a collaboration of corporate and public organizations, focuses on addressing the cancer problem in South Africa by expanding access to cancer therapies & diagnosis and developing a technologically advanced healthcare infrastructure. Furthermore, in precision medicine, wearables play a crucial role in capturing and analyzing data that can be utilized for personalized diagnostics, disease management, and preventive care.
Wearable devices can track changes in physiological parameters and detect early warning signs of diseases, allowing for timely intervention and proactive healthcare. Integrating wearables with advanced analytics and ML algorithms further enhances their potential in precision medicine. By leveraging AI and data analytics, wearables can identify patterns, detect anomalies, and provide valuable insights for disease monitoring, medication adherence, and lifestyle modifications. The growing demand for digital healthcare and clinical health records is another key factor driving the market growth. The increasing adoption of Electronic Health Records (EHRs) and digital health platforms has led to the generation of vast amounts of patient data.
AI technologies, such as ML and deep learning algorithms, have the potential to analyze and derive insights from this data, enabling personalized and precise medical interventions. For instance, in September 2024, Roche expanded its digital pathology platform by integrating over 20 advanced AI algorithms from eight new partners. This collaboration aims to enhance cancer research and diagnosis by providing pathologists and scientists with high-value AI insights, supporting precision medicine for more targeted cancer treatments.
The COVID-19 pandemic positively impacted the market, presenting opportunities for AI-powered computer systems to combat the virus. Various technology companies and startups have been actively working toward mitigating, preventing, and containing the spread of the virus. The outbreak of COVID-19 has also accelerated the growth of the AI market in other domains, driven by the widespread adoption of remote work policies necessitated by the pandemic.
Market Dynamics
The market growth is primarily driven by increasing investments in R&D and rising demand for personalized medications. In addition, growing prevalence of cancer and the rising adoption and launch of AI-driven precision medicine in oncology serves as a significant growth driver.
Technological advancements in cancer biology have revolutionized our understanding of the disease and significantly impacted cancer research and treatment. Precision medicine aims to customize medical care according to individual characteristics, risks, and responses to treatments. The rising adoption and launch of AI-driven precision medicine in oncology serves as a potent growth driver. In January 2024, Penn Medicine researchers created iStar, an AI tool that analyzes gene activities in medical images. This tool provides single-cell insights into diseases in tissues & microenvironments. iStar has the capability to automatically identify important antitumor immune formations known as "tertiary lymphoid structures." These structures are linked to a patient's probable survival and favorable response to immunotherapy, a cancer treatment that requires precise patient selection. As a result, iStar can help identify patients who would benefit the most from immunotherapy.
Cancer treatment is often challenged by the complexity and heterogeneity of tumors, which is expected to lead to treatment resistance and relapse. Traditional approaches typically apply maximum tolerated doses (MTD) of chemotherapy or fixed schedules, which may not optimally control tumor growth or prevent drug resistance. Researchers at the University of Oxford have demonstrated how artificial intelligence (AI), specifically deep reinforcement learning (DRL), can be used to design adaptive, personalized cancer treatment strategies that dynamically adjust therapy based on individual patient responses. This approach promises to improve treatment effectiveness and delay cancer recurrence.
The study demonstrates the feasibility of combining AI and mathematical modeling to tailor cancer treatments, paving the way for broader applications across cancer types.
"This study illustrates how combining mathematical modeling with the power of AI could have significant impact on the clinical treatment of cancer, increasing effectiveness and reducing cost."
— Professor Philip Maini, Director, Wolfson Centre for Mathematical Biology, University of Oxford
Analyst Key Takeaways: The University of Oxford's research showcases how AI-driven adaptive therapy can revolutionize cancer treatment by personalizing drug schedules to individual tumor dynamics. By extending relapse-free survival and improving treatment efficiency, this approach addresses key challenges in oncology and holds promises for transforming clinical practice toward truly personalized medicine.
Targeted drug development
The growing focus on precision medicine and targeted drug development is a major driver for AI in drug repurposing, highlighting a shift from “one‑size‑fits‑all” indications to biomarker-defined patient subsets. Precision programs now require matching existing or pipeline drugs to molecularly characterized populations. AI-enabled repurposing platforms can integrate genomics, transcriptomics, digital pathology, and clinical outcomes data, enabling the discovery of new uses for approved drugs in narrowly defined subgroups.
Moreover, collaborations such as the BostonGene–Kyoto University partnership in November 2025 demonstrate how AI-powered molecular profiling is being integrated into precision drug development workflows to match existing compounds with defined patient subgroups. As treatment paradigms shift from broad-spectrum therapies to biomarker-directed interventions, AI-supported drug repurposing provides an efficient means of delivering targeted solutions, eliminating lengthy discovery cycles. Such projects generate detailed, multi-omic and immune-system signatures that guide both the development of novel agents and the repositioning of existing drugs or combinations for biomarker-defined cohorts.
"This collaboration will generate actionable insights into the tumor microenvironment and immune landscape of esophageal cancer. Combining Kyoto University’s clinical expertise and BostonGene’s AI-powered analytics, we will refine and advance precision treatment strategies for ESCC patients."
-Yukimasa Shiotsu, PhD, President of BostonGene Japan
Similarly, BostonGene’s ongoing collaborations with Takeda, Mount Sinai, and the SWOG Cancer Research Network underscore the transformative impact of AI-enabled biomarker identification and immune system profiling on therapeutic decision-making in oncology.
-
In September 2025, BostonGene and Mount Sinai partnered on a prospective precision-medicine study for multiple myeloma patients. The collaboration is expected to use BostonGene’s AI-driven molecular and immune profiling to identify biomarkers, predict treatment response, and guide personalized therapeutic decisions. The study aims to improve outcomes through data-driven, individualized disease characterization.
-
In August 2025, BostonGene and Takeda entered an immuno-oncology research partnership to utilize BostonGene’s AI-powered multiomics platform in early-stage trials. This partnership aims to optimize patient selection, refine indication strategies, and identify biomarkers for response and toxicity, thereby clarifying the mechanisms of investigational therapies and improving cancer care and drug development outcomes.
-
In July 2025, BostonGene and the SWOG Cancer Research Network are collaborating on the NCI‑supported PRISM S2409 multicohort Phase II trial in extensive‑stage small cell lung cancer.
-
In December 2024, Neurimmune and AICURA Medical formed a strategic collaboration to utilize advanced AI in the development of Alzheimer’s disease therapeutics, focusing on AI-designed clinical programs to predict disease status, treatment response, and safety risks.
Such initiatives demonstrate the effectiveness of AI in identifying mechanistic overlaps between diseases and existing drugs, thereby facilitating the rapid discovery of repurposable candidates with a high probability of clinical response.
Furthermore, key players such as Owkin, through collaborations with AWS and the development of generative AI pipelines, are advancing precision-medicine-focused drug development models that combine real-world clinical data with AI-driven biological predictions. These platforms enhance the ability to identify repurposing targets by modeling disease mechanisms at individual and population levels. As precision medicine ecosystems continue to integrate such computational infrastructures, the need for repurposing-oriented AI tools increases, thus leveraging existing drug libraries to offer faster and economically viable pathways to achieve personalized treatments.
The development and deployment of artificial intelligence solutions for precision medicine are subject to complex, evolving regulatory requirements, posing a significant challenge to market growth. AI-driven precision medicine platforms often process sensitive patient information, including genomic data, medical imaging, electronic health records, and biomarker profiles, and are therefore subject to strict regulatory oversight. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and other national authorities require extensive evidence demonstrating the safety, effectiveness, reliability, and clinical validity of AI-based tools before they can be adopted in routine healthcare settings. Unlike conventional software, AI models frequently evolve through continuous learning and algorithm updates, creating additional challenges for regulators seeking to ensure consistent performance over time. Companies must conduct rigorous validation studies, clinical evaluations, risk assessments, and documentation processes to satisfy regulatory expectations. These requirements are likely to significantly increase development costs and extend commercialization timelines. For emerging companies and startups, the financial and operational burden of regulatory compliance is anticipated to delay product launches and limit innovation, thereby restraining broader adoption of AI technologies in precision medicine.
Market Concentration & Characteristics
The chart below illustrates the relationship between industry concentration, industry characteristics, and industry participants. The x-axis represents the level of industry concentration, ranging from low to high. The y-axis represents various industry characteristics, including industry competition, level of partnerships & collaboration activities, degree of innovation, impact of regulations, and regional expansion. The agentic AI in healthcare market is fragmented, with the presence of several emerging solution providers dominating the market. The degree of innovation is high, and the level of merger and acquisition activities is moderate. The impact of regulations on industry and the regional expansion of industry is high.
Technological advancements driven by the increasing demand for early and accurate disease treatment, improving patient outcomes, further results in significant innovations. For instance, in October 2024, Aignostics announced securing a USD 34 million Series B funding round to expand precision medicine applications with AI. The funding is expected to support new product development for biopharmaceutical clients, drive U.S. market growth, and advance foundational models in pathology through collaboration with Mayo Clinic. With precision medicine's increasing complexity, biopharmaceutical firms are leveraging AI to improve the efficiency, performance, and scalability of computational pathology for drug development and diagnostics.
The M&A activities, such as mergers, acquisitions, and partnerships, enable companies to expand geographically, financially, and technologically. For instance, in June 2021, Exscientia acquired Allcyte, an AI-based precision medicine firm, to expand its capabilities in evaluating drug responses within patient tumor environments. This acquisition enhances Exscientia’s translational abilities, as Allcyte’s platform uses AI for high-resolution single-cell analysis, clinically validated through studies like EXALT-1. Exscientia aims to integrate this technology across drug discovery to patient selection, furthering its patient-centric AI applications.
The industry has a significant impact of regulations, which are overlooked by several regulatory bodies, as per the region. For instance, the FDA issued a guidance draft in April 2023 to establish a regulatory framework for AI/ML-based devices. The draft outlines the least burdensome approach for continuously improving ML-based Device Software Functions (ML-DSF). The aim is to enhance patient access to secure and effective AI/ML-based devices, ensuring the promotion and protection of general health.
The industry's regional expansion activities are driven by an increasing demand to advance precision medicine, customer base, and technology. For instance, in October 2024, Israel-based Quris-AI announced the acquisition of assets from U.S.-based Nortis. Nortis’s Kidney-on-Chip models, which advance in-vitro drug testing and personalized medicine, are expected to be integrated with Quris-AI’s ML models and patented patient-on-chip system. This combination aims to enhance predictions of human drug reactions, allowing earlier elimination of potentially harmful drug candidates in the development pipeline.
Analyst Perspective
The Artificial Intelligence in Precision Medicine market is emerging as a transformative healthcare segment, driven by the increasing availability of genomic data, advances in computational biology, and growing demand for personalized treatment approaches. Healthcare providers, pharmaceutical companies, and research institutions are leveraging AI technologies to analyze complex biological, clinical, imaging, and molecular datasets to identify disease patterns, predict treatment responses, and optimize therapies. The growing prevalence of cancer, rare diseases, cardiovascular disorders, and other complex conditions is further accelerating adoption. The competitive landscape is shaped by the convergence of artificial intelligence, genomics, cloud computing, and advanced analytics, with machine learning supporting drug discovery, biomarker identification, clinical trial optimization, disease risk prediction, and personalized treatment selection. Companies with robust AI capabilities, access to large healthcare datasets, strong research partnerships, and scalable technology infrastructure will be best positioned to capitalize on long-term growth opportunities in this rapidly evolving market.
Component Insights
By component, software segment held the largest market share of 42.0% in 2025. In addition, this segment is expected to register fastest growth over the forecast period. The significant adoption of AI-powered software solutions for precision medicine by institutions, providers, and patients is expected to drive the growth of the software segment. In June 2023, Illumina Inc. introduced PrimateAI-3D, an advanced AI algorithm that accurately predicts disease-causing genetic mutations. PrimateAI-3D is expected to be widely accessible to the genomics community through integration within Illumina Connected Software.
Hardware segment is expected to grow at significantly during the forecast period. The growth is primarily driven by the need for high computational power to handle large biomedical datasets, ensure fast processing for real-time diagnostics, and support advanced AI algorithms in personalized treatments. For instance, in July 2024, Insilico introduced PandaOmics Box, an AI-driven hardware platform for on-premise personalized medicine and drug discovery research. The platform integrates PandaOmics, Insilico's proprietary generative biology AI software, with a comprehensive scientific database and high-performance hardware, including chip-level confidential computing capabilities, to enhance data security and computational efficiency.
Technology Insights
By technology, the deep learning segment held the largest market share of 33.5% in 2025. However, the natural language processing segment is anticipated to witness the fastest growth with a CAGR over the forecast period. The growth is driven by advancements in data center capabilities, increased processing power, and the ability to perform tasks autonomously. Deep learning algorithms enable the integration and modeling of diverse patient data across different modalities and time, leading to improved predictions & personalized treatment recommendations. For instance, in May 2023, GE HealthCare received FDA 510(k) clearance for Precision DL, an image processing deep learning-based software within its expanding Effortless Recon DL portfolio. Precision DL delivers image quality advancements linked with Time-of-Flight (ToF) hardware-based reconstruction, such as enhanced contrast recovery, contrast-to-noise ratio, and higher quantitative accuracy.
Natural language processing (NLP) segment is anticipated to grow at a significant CAGR over the forecast period. NLP is anticipated to play a crucial role in expediting the healthcare decision-making process. The benefit of establishing effective algorithms depends on the data quality obtained. A quicker decision-making process will allow physicians to focus on value-added treatment. For instance, in November 2023, GenomOncology announced that City of Hope, a U.S. cancer research and treatment institution, is expected to enhance its NLP pipeline using HopeIQ, a data enablement solution developed by City of Hope and powered by GenomOncology's igniteIQ platform. City of Hope has demonstrated progress in improving patient care through its precision medicine initiatives.
Therapeutic Application Insights
By therapeutic application, the oncology segment held the largest market share of 30.0% in 2025. However, the neurology segment is expected to register fastest growth over the forecast period. For instance, In June 2024, Caris Life Sciences expanded its network of cancer institutions focused on advancing patient outcomes through precision medicine innovations by including the Caris Precision Oncology Alliance (POA).
"We are thrilled to welcome Mass General Cancer Center, one of the world's most respected centers, to the Caris Precision Oncology Alliance. We're eager to work with their researchers and investigators on our shared mission of improving outcomes of all patients affected by cancer through precision oncology research."
-George W. Sledge, Jr., MD, EVP and Chief Medical Officer of Caris
Neurology segment is expected to grow at the fastest CAGR during the forecast period. The growth is attributed to the increasing prevalence of neurological disorders, such as Alzheimer's and Parkinson's disease, which necessitate early and accurate diagnosis. Moreover, advancements in AI technologies, particularly in imaging and data analysis, enhance the ability to identify complex neurological conditions, improving patient outcomes. For instance. in April 2024, NeuroSense Therapeutics Ltd. collaborated with Genetika+ to advance drug development for Alzheimer's Disease (AD). This multi-phase partnership, initiated within NeuroSense's ongoing Phase 2 AD clinical trial, utilizes Genetika+'s technology to derive frontal cortex neurons from patient blood samples, enabling in vitro quantification of drug-induced neuronal plasticity.
Regional Insights
North America dominated the AI in precision medicine market with the largest revenue share of 53.3% in 2025. Growth of the market is attributed to the strategic presence of major players, such as Abbott; Danone; Targeted Medical Pharma, Inc.; Nestlé; and Mead Johnson & Company, LLC. For instance, in July 2022, Certara, Inc., which pioneered biostimulation, announced a two-year collaboration with Memorial Sloan Kettering Cancer Center to build new biosimulation software. This collaboration helps companies develop a biosimulation platform for CAR T-cell treatment. Furthermore, CAR T-cell treatment, known as immunotherapy, employs immune system T-cells, which have experienced a unique modification to combat certain types of blood cancer. The increasing demand for personalized treatment is the primary factor driving market expansion in the U.S.
U.S. Artificial Intelligence in Precision Medicine Market Trends
The AI in precision medicine market in the U.S. held the largest share in the North America region in 2025. The growth is driven by advanced healthcare infrastructure, substantial investment in research and development, and a focus on improving patient outcomes. For instance, in May 2024, U.S. Precision Medicine, Inc. announced its plans to leverage advanced AI technology to support independent research demonstrating the efficacy of its small molecule candidate in targeting and eliminating breast cancer cells.
Europe Artificial Intelligence in Precision Medicine Market Trends
The AI in precision medicine market in Europe is poised to grow at the fastest CAGR over the forecast period. The rising demand for reducing healthcare expenditure and growing patient health-related digital information datasets are fueling market growth. The rising global geriatric population, changing lifestyle, and growing prevalence of chronic illnesses have increased the need for early disease diagnosis and treatment. The increasing government initiatives are fueling regional market growth. The European Cancer Imaging Initiative aims to help innovators and researchers translate real-world oncology data on the quality and scale required to develop new cancer detection, diagnosis, and treatment solutions, especially those based on AI.
The AI in precision medicine market in the UK is expected to grow significantly over the forecast period. Partnerships between various healthcare institutes and industry players contribute to research advancements and practical applications of AI technologies. For instance, in February 2024, a collaborative initiative involving Durham University, the Royal Marsden Hospital, the Institute of Cancer Research (ICR), and tech-bio firm Concr received a USD 1.08 million (EUR 1 million) Innovate UK grant. The AI-VISION project aims to drive advancements in precision medicine.
The AI in precision medicine market in Germany is expected to grow substantially over the forecast period. The growth is divern by increasing strategic initiatives undertaken by market players to advance cancer therapy. For instance, in January 2024, Quibim announced a collaboration with Merck KGaA to develop advanced precision medicine technologies aimed at various cancers.
Asia Pacific Artificial Intelligence in Precision Medicine Market Trends
The AI in precision medicine market in Asia Pacific is expected to grow significantly over the forecast period. The AI in precision medicine market in Asia-Pacific is driven by rising investments in healthcare AI, growing demand for personalized treatments due to a high prevalence of chronic diseases, and supportive government initiatives promoting healthcare innovation. Moreover, various exhibitions provide a platform for market players to introduce advanced healthcare solutions. For instance, in August 2024, Taiwan Web Service announced new enhancements in precision medicine at the BIO Asia-Taiwan Exhibition 2023. Through a collaboration with the Industrial Technology Research Institute, the partnership integrates AI applications with biomedical engineering to develop AI-enabled biomedical tools.
In Japan, the AI in precision medicine market benefits from advanced healthcare infrastructure and strong government support for AI-driven medical innovations, particularly for addressing age-related diseases in its aging population. Collaborations between tech companies, research institutions, and healthcare providers reinforce Japan’s focus on precision medicine. High R&D investment in genomics and bioinformatics and a robust regulatory environment promoting healthcare advancements accelerate AI integration in diagnostics and personalized treatment.
Key Artificial Intelligence in Precision Medicine Company Insights
The market is highly competitive and is dominated by a few large competitors. Key players are implementing various strategies, such as mergers, partnerships, collaborations, and acquisitions, to enhance their market presence.
Several players are actively implementing strategic plans to meet the growing demand. For instance, in May 2021, AdventHealth, a nonprofit healthcare organization, announced its collaboration with Sema4, a health intelligence company. Through the utilization of Sema4's software platform and tools, AdventHealth aims to integrate genomic and clinical data. This collaboration expands AdventHealth's existing genomics and personalized health initiative, which includes investments in precision medicine research, as well as genetic testing, counseling, and sequencing service. Some of the prominent players in the global AI in precision medicine market include:
Key Artificial Intelligence in Precision Medicine Companies
The following key companies have been profiled for this study on the artificial intelligence in precision medicine market.
-
BioXcel Therapeutics Inc.
-
Sanofi
-
NVIDIA Corporation
-
Alphabet Inc. (Google Inc.)
-
IBM
-
Microsoft
-
Intel Corp.
-
AstraZeneca plc
-
GE HealthCare
-
Enlitic, Inc.
Competitive Benchmarking
Operating Strategies
Competitive Edge
Weaknesses
Established Players (Sanofi, NVIDIA Corporation, Alphabet Inc. (Google), IBM, Microsoft, Intel Corp., AstraZeneca plc, GE HealthCare)
- Expand AI-driven precision medicine capabilities through strategic partnerships, acquisitions, cloud platform development, genomic research collaborations, and integration of AI across drug discovery, clinical development, diagnostics, and personalized treatment planning.
- Invest in machine learning, deep learning, multimodal healthcare data analytics, digital pathology, medical imaging, genomics, and real-world evidence platforms to strengthen market leadership.
- Focus on developing end-to-end precision medicine ecosystems that integrate genomic data, clinical records, imaging datasets, and predictive analytics to support individualized patient care and therapeutic decision-making.
- Strong global brand recognition, extensive R&D capabilities, advanced AI infrastructure, and significant investments in healthcare innovation.
- Access to large-scale healthcare datasets, cloud computing platforms, high-performance computing resources, established regulatory expertise, and broad partnerships across healthcare, pharmaceutical, and research institutions support rapid development and commercialization of AI-powered precision medicine solutions.
- High development costs associated with AI model training, data acquisition, validation, and regulatory compliance.
- Challenges related to data privacy, interoperability, algorithm transparency, and integration into existing clinical workflows may slow adoption.
- Complex regulatory requirements and lengthy validation processes can also impact commercialization timelines.
Emerging & Specialized Players (BioXcel Therapeutics Inc., Enlitic, Inc.)
- Focus on specialized AI applications in drug discovery, clinical decision support, medical imaging analytics, biomarker identification, and patient stratification.
- Leverage proprietary algorithms, targeted therapeutic expertise, innovative data science approaches, and collaborative partnerships with healthcare providers, pharmaceutical companies, and research organizations to strengthen competitive positioning.
- Greater agility in developing innovative AI solutions for specific precision medicine applications.
- Ability to rapidly adapt to technological advancements, focus on niche clinical challenges, and deliver highly specialized platforms for diagnostics, imaging interpretation, and personalized treatment optimization.
- Limited financial resources, narrower product portfolios, and lower global market presence compared to large technology and pharmaceutical companies.
- Dependence on partnerships, regulatory approvals, and access to high-quality healthcare datasets may restrict scalability and market expansion.
Recent Developments
-
In October 2024, Aidoc and NVIDIA announced the development of a framework to enhance the deployment and integration of AI tools in healthcare. Named the Blueprint for Resilient Integration and Deployment of Guided Excellence (BRIDGE), this guideline aims to speed up AI adoption across the healthcare sector.
-
In October 2024, GE HealthCare announced announced to lead a consortium dedicated to synthetic data generation for AI in healthcare. The initiative includes industry partners such as Novo Nordisk, Gates Ventures, and Pfizer, alongside academic collaborators like the Fraunhofer Institute, La Fe University, and the University of Bologna. The consortium aims to develop synthetic datasets to enhance AI algorithm training in healthcare applications.
“In the era of precision medicine where treatments target specific gene mutations, new tools are essential to protect patient data privacy. Whole genome sequencing, digital imaging, and electronic health records represent an individual's unique ID, all of which are crucial for providing the best possible care. Yet safeguarding personal data privacy is non-negotiable. Generating effective synthetic databases through artificial intelligence is the only viable way to uphold privacy while advancing precision medicine. Generation of efficient synthetic data bases by using artificial intelligence is the unique way to pursue the goals of maintaining data privacy while offering the tools to advance in precision medicine.”
~ Guillermo Sanz, Scientific Director at IlSLaFe, Hospital Universitario y Politécnico la Fe
-
In May 2023, Google Cloud introduced new AI tools to advance precision medicine and life sciences. The Target and Lead Identification Suite supports pharmaceutical researchers in predicting protein structures and analyzing amino acid functions to enhance drug discovery. The Multiomics Suite facilitates genomic data interpretation, assisting in developing and applying precision therapeutics.
Artificial Intelligence In Precision Medicine Market Report Scope
Report Attribute
Details
Market size in 2025
USD 2.4 billion
Estimated market size in 2026
USD 3.4 billion
Projected market size by 2033
USD 32.5 billion
Growth rate
CAGR of 38.3% from 2026 to 2033
Historical data
2021 - 2024
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Technology, component, therapeutic application, and region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Norway; Denmark; Sweden; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
BioXcel Therapeutics Inc.; Sanofi; NVIDIA Corporation; Alphabet Inc. (Google Inc.); IBM; Microsoft; Intel Corp.; AstraZeneca plc; GE HealthCare; Enlitic, Inc.
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Artificial Intelligence In Precision Medicine Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global artificial intelligence in precision medicine market report based on component, technology, therapeutic applications, and region:
-
Component Outlook (Revenue, USD Million, 2021 - 2033)
-
Software
-
Hardware
-
Services
-
-
Technology Outlook (Revenue, USD Million, 2021 - 2033)
-
Deep Learning
-
Querying Method
-
Natural language processing
-
Context aware processing
-
-
Therapeutic Application Outlook (Revenue, USD Million, 2021 - 2033)
-
Oncology
-
Cardiology
-
Neurology
-
Respiratory
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Norway
-
Denmark
-
Sweden
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
South Korea
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East and Africa (MEA)
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The artificial intelligence in precision medicine market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each cryptocurrency payment apps segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment – Component
Revenue capture definition
Software
AI-powered software platforms and applications used in precision medicine to analyze genomic, clinical, imaging, proteomic, and real-world patient data. These solutions support disease prediction, biomarker discovery, patient stratification, clinical decision-making, drug development, and personalized treatment planning.
Hardware
Physical computing infrastructure and devices that enable AI-driven precision medicine applications. This includes high-performance computing systems, servers, GPUs, data storage systems, sequencing platforms, edge computing devices, and other hardware required for processing large-scale biomedical datasets.
Services
Professional and managed services supporting the implementation, integration, maintenance, validation, consulting, training, and optimization of AI solutions in precision medicine. These services help healthcare providers, research organizations, and pharmaceutical companies maximize the value of AI technologies.
Segment – Technology
Revenue capture definition
Deep Learning
A subset of artificial intelligence and machine learning that utilizes multi-layered neural networks to identify complex patterns within large and diverse datasets. In precision medicine, deep learning is widely used for genomic analysis, medical imaging interpretation, biomarker identification, disease prediction, and personalized therapy selection.
Querying Method
AI-enabled data retrieval and analytics techniques that allow users to search, extract, correlate, and analyze information from large healthcare, genomic, clinical, and research databases. These methods facilitate evidence generation, patient cohort identification, and informed clinical decision-making.
Natural Language Processing (NLP)
AI technology that enables computers to understand, interpret, and analyze unstructured text and spoken language from sources such as electronic health records (EHRs), physician notes, clinical literature, pathology reports, and research publications. NLP helps transform unstructured data into actionable clinical insights.
Context-Aware Processing
AI systems capable of interpreting and analyzing data within the broader context of a patient's clinical history, genetic profile, lifestyle factors, environmental influences, and treatment history. This technology enhances the accuracy and personalization of clinical recommendations and therapeutic decisions.
Segment – Therapeutic Application
Revenue capture definition
Oncology
Application of AI in precision cancer care to support early detection, molecular profiling, biomarker discovery, tumor characterization, treatment selection, prognosis prediction, and personalized oncology therapies based on individual patient and tumor characteristics.
Cardiology
Use of AI-driven precision medicine tools for the diagnosis, risk assessment, prevention, monitoring, and treatment of cardiovascular diseases. These solutions analyze genetic, imaging, and clinical data to support personalized cardiovascular care and improve patient outcomes.
Neurology
AI applications focused on the diagnosis, monitoring, and treatment of neurological and neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, and stroke. AI helps identify disease patterns and optimize individualized treatment strategies.
Respiratory
Utilization of AI technologies to support personalized management of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other lung disorders through predictive analytics, risk stratification, and treatment optimization.
Others
Includes precision medicine applications in therapeutic areas such as infectious diseases, rare diseases, endocrinology, immunology, gastroenterology, nephrology, metabolic disorders, and autoimmune conditions where AI supports personalized diagnosis and treatment decisions.
Estimation Model
Market Estimation Process
Market-specific Research Models:
Consensus-Based Estimates & Forecasting
The AI in precision medicine market presents emerging to dominant opportunities, featuring global key players such as BioXcel Therapeutics Inc.; Sanofi; NVIDIA Corporation; Alphabet Inc. (Google Inc.); IBM; Microsoft; Intel Corp.; AstraZeneca plc; GE HealthCare; Enlitic, Inc. To ensure a holistic approach, the GVR research team adopted a comprehensive methodology, considering multiple companies worldwide and utilizing various variables for data accuracy.
Our methodology included
-
Model 1: Commodity Flow Analysis - For public players, annual reports were referenced. For private players, premium paid data sources such as S&P Global, Crunchbase, ZoomInfo, RocketReach, etc., were used for the latest revenue insights.
-
Model 2: Parent Market Analysis
-
Model 3: Country-level Multivariate Analysis Assumptions
-
Model 4: Segment-level Multivariate Analysis Assumptions
-
Model 5: Artificial Intelligence in Precision Medicine Market CAGR Calculations
Model 1: Commodity Flow Analysis
Commodity flow analysis was employed to track the movement of AI in precision medicine through the value chain, from technology providers to end users. This analysis provided insights into demand generation points, intermediary roles, and ultimate consumption patterns.
Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
AI in Precision Medicine Adoption & Personalized Healthcare Analysis
Developed a tailored analysis of the global Artificial Intelligence in Precision Medicine market focused on AI-enabled diagnostics, predictive analytics, genomic interpretation, biomarker discovery, clinical decision support, disease risk assessment, and personalized treatment planning. The study assessed adoption trends across hospitals, research institutions, pharmaceutical companies, biotechnology firms, diagnostic laboratories, and healthcare providers while evaluating advancements in genomics, multi-omics technologies, and data-driven healthcare initiatives influencing market growth.
Enables stakeholders to understand evolving precision medicine trends, identify high-growth application areas, assess personalized healthcare opportunities, and evaluate the impact of AI-driven insights on diagnostic accuracy, treatment optimization, patient outcomes, and long-term market expansion.
Genomics Analytics, Drug Development & Clinical Decision Support Assessment
Delivered a customized evaluation of AI utilization across genomic sequencing analysis, biomarker identification, companion diagnostics, patient stratification, clinical trial optimization, drug discovery, and therapeutic response prediction. The analysis assessed machine learning algorithms, deep learning models, natural language processing, clinical decision support systems, healthcare provider adoption patterns, and real-world evidence integration supporting individualized patient care and targeted therapies.
Provides actionable insights into commercially attractive application segments, emerging technology trends, evolving clinical requirements, and growth opportunities associated with accelerated drug development, improved treatment efficacy, optimized clinical trials, reduced healthcare costs, and enhanced patient-centric care.
Healthcare Data Infrastructure, Regulatory Environment & Competitive Landscape Assessment
Conducted a focused assessment of the AI in Precision Medicine ecosystem, including genomic databases, cloud computing platforms, healthcare data integration systems, interoperability frameworks, cybersecurity requirements, regulatory compliance standards, and competitive positioning. The analysis evaluated implementation challenges, data privacy considerations, algorithm transparency requirements, reimbursement trends, technology adoption barriers, and competitive differentiation strategies among AI technology providers, life sciences companies, and precision medicine solution developers.
Supports strategic planning for AI platform development, precision medicine initiatives, pharmaceutical partnerships, technology investments, regulatory compliance, and market entry strategies by identifying adoption drivers, operational challenges, revenue opportunities, data infrastructure requirements, and competitive advantages across the global Artificial Intelligence in Precision Medicine value chain.
Frequently Asked Questions About This Report
The global artificial intelligence in precision medicine market size was valued at USD 2.4 billion in 2025 and is expected to reach 3.4 billion in 2026.
The global artificial intelligence in precision medicine market size is expected to grow at a compound annual growth rate of 38.3% over the forecast period from 2026 to 2033 and is expected to reach 32.5 billion in 2033.
North America dominated with a 53.3% revenue share in 2025.
Asia Pacific is the fastest-growing region over the forecast period.
The software segment led with a 42.0% revenue share in 2025, and is the fastest-growing segment.
The oncology segment led with a 30.0% revenue share in 2025, while neurology is the fastest-growing segment.
The deep learning segment led with a 33.5% revenue share in 2025, while natural language processing is the fastest-growing segment.
Some of the key players of the artificial intelligence in precision medicine market are: BioXcel Therapeutics Inc.; Sanofi; NVIDIA Corporation; Alphabet Inc. (Google Inc.); IBM; Microsoft; Intel Corp.; AstraZeneca plc; GE HealthCare; Enlitic, Inc.
The key factors driving artificial intelligence in precision medicine market are increasing investments in R&D and rising demand for personalized medications. In addition, growing prevalence of cancer and the rising adoption and launch of AI-driven precision medicine in oncology serves as a significant growth driver.
About the Author(s)
Healthcare IT Research Team
Healthcare · Healthcare ITThis report was authored by the healthcare it research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the healthcare it segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs — add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
